Lund, Sweden, 2015-04-27 14:57 CEST (GLOBE NEWSWIRE) --
EXINI and FUJIFILM RI Pharma have agreed to develop version 2.0 of the software EXINI heart (cardioREPO) in collaboration with renowned Japanese university hospitals. EXINI heart was launched onto the Japanese market a year ago and is currently used in well over 500 hospitals throughout Japan.
EXINI will be managing the project in close collaboration with FUJIFILM RI Pharma and well-known Japanese university hospitals. The objective is to further enhance the artificial intelligence and other important features of the software.
The collaboration combines EXINI's deep knowledge in machine learning and clinical databases with FUJIFILM RI Pharma’s application expertise and close contact with end users. The project will be funded by FUJIFILM RI Pharma and is expected to last 14 months.
“Much like with our first product in Japan, Bonenavi, we now pursue an even higher grade of exclusive adaptation of our heart software to Japanese needs and requirements in close collaboration with FUJIFILM RI Pharma and Japanese physicians for reaching our mutual goals”, comments Magnus Aurell CEO EXINI Diagnostics AB.
About EXINI heart (cardioREPO) – cardiology
CardioREPO is an advanced customization of the diagnostic software system EXINI heart, developed for the Japanese market to provide clinics and specialists with advanced information crucial to managing patients suffering from suspected or known ischaemic heart conditions e.g. heart attacks or angina.
For more information, please contact:
Magnus Aurell, CEO
Phone: +46 46-286 54 25
E-mail: magnus.aurell@exini.com
About EXINI Diagnostics AB (publ)
EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as cancer, coronary heart disease, dementia and Parkinson's disease. EXINI is listed on the stock market Nasdaq First North and has about 1000 shareholders. Consensus acts as Certified Adviser.
________________________________________________________________________
EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden
Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com
